SCHEMBL3011144

SCHEMBL3011144

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC)cc4OC)CC3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
F2RL3 Q96RI0 7/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
RAB9A P51151 1/20 0.35
CYP19A1 P11511 1/20 0.35
CNR2 P34972 1/20 0.35
GPR6 P46095 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018545 0.94 ALDH1A1 (0.41) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3016465 0.93 ALDH1A1 (0.42) MAPTLMNAALDH1A1HSD17B10KMT2A
SCHEMBL3014322 0.93 MAPT (0.38) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3005339 0.92 MAPK1 (0.37) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3006114 0.91 MAPT (0.40) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3014404 0.91 MAPT (0.39) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3015933 0.91 MAPT (0.41) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3016729 0.90 ALDH1A1 (0.41) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3009170 0.90 MAPT (0.39) MAPTLMNATDP1F2RL3ALDH1A1
SCHEMBL3002013 0.88 MAPT (0.37) MAPTLMNATDP1F2RL3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.